Aoyama Taro, Kakizaki Fumihiko, Miyoshi Hiroyuki, Sonoshita Masahiro, Maekawa Hisatsugu, Itatani Yoshiro, Kawada Kenji, Matsusue Ryo, Ikai Iwao, Moriyoshi Koki, Sakurai Takaki, Obama Kazutaka, Sato Tosiya Shun, Sakai Yoshiharu, Taketo Makoto Mark
Colon Cancer Project, Kyoto University Hospital-iACT, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
BJC Rep. 2025 Jul 25;3(1):53. doi: 10.1038/s44276-025-00163-0.
We previously reported that TRIO pY2681, a novel prognostic biomarker for CRC, can be detected by polyclonal antibodies (pAb). We have now developed a novel monoclonal antibody (mAb) that recognizes TRIO pY2681. This study aims to assess the utility of immunohistochemical (IHC) staining using the TRIO pY2681 mAb as a prognostic marker for CRC in clinical practice.
IHC using TRIO pY2681 mAb was performed on surgical specimens from 357 CRC patients at Kyoto Medical Center and 320 at Kyoto University Hospital. Based on the results, we conducted a retrospective outcome analysis.
TRIO pY2681 mAb exhibited significantly higher titers than pAb. In both cohorts of all stages, TRIO pY2681 IHC positivity correlated with shorter disease-specific survival (DSS) (HR, 1.67; 95% CI, 1.00-2.79; P = 0.046, and HR, 5.84; 95% CI, 2.26-15.1; P < 0.001) and relapse-free survival (RFS) (HR, 1.92; 95% CI, 1.15-3.22; P = 0.011, and HR, 4.36; 95% CI, 2.17-8.76; P < 0.001). The trend persisted in stage III. Multivariate analysis confirmed TRIO pY2681 IHC positivity as an independent prognostic factor for RFS.
The novel TRIO pY2681 mAb identifies CRC patient subsets with poorer prognoses, enhancing prognostic precision in clinical settings.
我们之前报道过，TRIO pY2681是一种用于结直肠癌的新型预后生物标志物，可通过多克隆抗体（pAb）检测到。我们现已开发出一种识别TRIO pY2681的新型单克隆抗体（mAb）。本研究旨在评估在临床实践中使用TRIO pY2681 mAb进行免疫组织化学（IHC）染色作为结直肠癌预后标志物的效用。
对京都医疗中心的357例结直肠癌患者和京都大学医院的320例患者的手术标本进行了使用TRIO pY2681 mAb的IHC检测。基于检测结果，我们进行了回顾性预后分析。
TRIO pY2681 mAb的效价显著高于pAb。在所有分期的两个队列中，TRIO pY2681 IHC阳性均与较短的疾病特异性生存期（DSS）（风险比[HR]，1.67；95%置信区间[CI]，1.00 - 2.79；P = 0.046，以及HR，5.84；95% CI，2.26 - 15.1；P < 0.001）和无复发生存期（RFS）（HR，1.92；95% CI，1.15 - 3.22；P = 0.011，以及HR，4.36；95% CI，2.17 - 8.76；P < 0.001）相关。该趋势在III期患者中持续存在。多变量分析证实TRIO pY2681 IHC阳性是RFS的独立预后因素。
新型TRIO pY2681 mAb可识别预后较差的结直肠癌患者亚组，提高临床环境中的预后预测准确性。
